The effect of lower salt exposure at haemodialysis on cardiac micro-injury, in home and self-care haemodialysis patients.
A randomised controlled trial of low versus normal dialysate sodium, to assess the effect on myocardial micro-injury in patients on home and self-care haemodialysis
The Centre for Clinical Research and effective practice (CCRep), registered with the New Zealand Charities Commission (ref# CC21537)
118 participants
Mar 26, 2012
Interventional
Conditions
Summary
The SOLID Trial (ACTRN12611000975998) is currently underway. Its hypothesis is that reduced sodium exposure through the use of lower dialysate sodium concentration will reduce cardiovascular morbidity in haemodialysis patients, by reducing inter-dialytic hypertension and LV mass. The Mac-Solid Extension trial will evaluate whether any benefit of lower dialysate sodium in reducing inter-dialytic hypertension and LV mass might be offset by increased rates of intra-dialytic hypotension and myocardial micro-injury.
Eligibility
Plain Language Summary
Simplified for easier understanding
This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Low dialysate [Na+] at 135mM up to (and including) 7 times per fortnight (average 3.5 times per week) at every haemodialysis treatment for 12 months. Dialysate Na+ will be set in service mode and locked to 135mM on patient's machine, so as machine defaults to 135mM every time it is turned on for the 12 month study period.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12614000070639